Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra phase 3 induction and maintenance study in ulcerative colitis
2025-521381-10-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week I-12 and Clinical remission at Week M-40. Planned start Dec 2025; status: authorised.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-521381-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521381-10-00.